Navigation Links
Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia
Date:1/3/2011

CLEVELAND, Jan. 3, 2011 /PRNewswire/ -- Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that the U.S. Food and Drug Administration (FDA) authorized commencement of a Phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischemia (CLI).  JVS-100 encodes Stromal-cell Derived Factor 1 (SDF-1), which has been shown in several pre-clinical studies to promote tissue repair through activation of natural stem-cell repair pathways, promotion of new blood vessel formation and prevention of on-going cell death.  The new trial builds on the JVS-100 cardiovascular program that includes a U.S. Phase I heart failure (HF) clinical trial for which the Company recently completed enrollment of 17 patients.

"Juventas is excited to extend its clinical pipeline to include treatment of patients with CLI," stated Rahul Aras, Ph.D., President & CEO for Juventas Therapeutics.  "With our heart failure and critical limb ischemia programs moving into mid-stage clinical trials, the Company is focused on leveraging its regenerative medicine platform to address a range of cardiovascular indications with the goal of providing novel therapies to patients with limited options."

The randomized, placebo-controlled study will evaluate the efficacy and safety of JVS-100 in 48 patients (36 JVS-100 treated; 12 placebo) with Rutherford Class IV or V CLI.  The clinical trial will measure several efficacy endpoints including time to amputation, transcutaneous oximetry (TcPO2), Ankle-Brachial Index (ABI) and ulcer closure.  

"Critical limb ischemia is a devastating disease for which there is currently no FDA-approved drug for treatment," said Douglas Losordo, M.D., Principal Investigator for the trial and Director of the Feinberg Cardiovascular Research Institute at the Northwestern University Feinberg S
'/>"/>

SOURCE Juventas Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Zenobia Therapeutics, Inc. Enters Into a Research Collaboration With Lundbeck for the Parkinsons Disease Target LRRK2
2. Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy
3. Talecris Biotherapeutics Announces Jury Verdict in Contract Dispute
4. ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program
5. Reportlinker Adds Global Bladder Cancer Therapeutics Industry
6. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
7. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
8. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
10. NASDAQ Grants Cell Therapeutics 180-Day Extension to Regain Compliance With Minimum Bid Price Rule
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... by group leader Yung-Eun Sung has announced that ... and nitrogen-doped graphenes which can be applied as ... cells. Yung-Eun Sung is both a group leader ... for Basic Science* (IBS) and a professor at ... great significance with regards to the development of ...
(Date:7/24/2014)... of Engineering at the University of Delaware, is ... in energy engineering, environmental sustainability and electronics. , ... rock with a well-defined, crystalline structure. At the ... decided that zeolites can separate molecules with size ... (one-tenth of a nanometer), making them useful to ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... Culture Market 2014-2018" report to their offering.  ... culture is the in vitro growth of plant or ... studies, and biopharmaceutical production. Cell culture is a crucial ... instruments and cell culture consumables are necessary for the ...
(Date:7/24/2014)... Your cell phone may stay charged ... storage capacity. , New research indicates that lithium-ion ... at Lawrence Livermore National Laboratory and ... components will perform as electrodes. , The growing ... for higher-performance batteries. Several key characteristics of lithium-ion ...
Breaking Biology Technology:University of Delaware researcher describes new approach for creating organic zeolites 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2Getting More Life out of Lithium-ion Batteries 2
... Reaches severance agreement with unionsSEATTLE, May 15 Cell ... that, as previously discussed in a press release on ... operations and has reached agreement with the employee union ... a reduction of CTI,s total headcount in Italy by ...
... (TSX:ONC, NASDAQ: ONCY ) announced today that data from ... at the 2009 American Society of Clinical Oncology (ASCO) Annual ... 29-June 2, 2009. The abstracts are available on the ASCO ... poster presentations, - Dr. Monica ...
... May 14 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc., (TSX: SDI), ... and a therapeutic targeting severe sepsis, today announced its ... 2009. , "This quarter, we achieved an important milestone ... Toraymyxin(TM) for the US market after thorough due diligence ...
Cached Biology Technology:Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses 2Oncolytics Biotech(R) Inc.'s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference 2Spectral announces first quarter 2009 results 2Spectral announces first quarter 2009 results 3Spectral announces first quarter 2009 results 4Spectral announces first quarter 2009 results 5Spectral announces first quarter 2009 results 6Spectral announces first quarter 2009 results 7
(Date:7/25/2014)... July 25, 2014 In the first broad-scale estimate of ... scientists and collaborators calculated that trees are saving more ... incidences of acute respiratory symptoms. , While trees, pollution ... less than 1 percent, the impacts of that improvement ... the reduced air pollution at nearly $7 billion every ...
(Date:7/25/2014)... of people lived on the land now called California, ... the availability of plants they used for food, fuel, ... to maintain desired habitat and natural resources. , Frank ... Southwest Station, will lead a field trip ... Ecological Society of America,s 99th Annual Meeting, in Sacramento, ...
(Date:7/25/2014)... scars on this false-color image from the Terra satellite show ... rash of wildfires in Eastern Russia. The burn scars ... background. The wildfires have broken across the remote parts ... this false-color image from the MODIS instrument, it is ... that continue. Two recent image features noted below show the ...
Breaking Biology News(10 mins):First national study finds trees saving lives, reducing respiratory problems 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... noses and Microsoft Windows, infamous blue screen of death ... being made by a new research report appearing online ... Specifically, scientists now know exactly why we sneeze, what ... not work properly. Much like a temperamental computer, our ...
... Olympic athletes may be the best trained and physically ... susceptible to back pain. BackPainRelief.net is releasing an infographic ... injuries can be avoided. (Photo: ... for a number of injuries, and back pain is ...
... (July 30, 2012) When the longest cells in the body ... is no easy task. This is in part because these ... one meter in adult humans which is a lot ... order to reach the "command center" of the cell,s nucleus. ...
Cached Biology News:Allergies? Your sneeze is a biological response to the nose's 'blue screen of death' 2Backpainrelief.net Tackles Sports Injuries with Infographic 2Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 2Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 3
... to Dideoxycytidine Dideoxycytidine is a cytidine analog ... inhibiting retroviral activity. Immunogen: Chemical ... Specificity: The specificity of the ddC antiserum ... moles of ddC to moles of ddC analog ...
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
... is designed with a variety of motion ... all in one unit. Shake, rock, roll ... compartments allow for hybridization and blotting procedures ... , The upper chamber uses a roller ...
... Concentrator, the SPD series takes the 'Classic' ... twist., The SPD121P SpeedVac comes equipped with ... runs; preventing samples from freezing; and allowing ... end-users preset level., Standard features on the ...
Biology Products: